Abstract 2259P
Background
Type I polarized macrophages (M1) play an anti-tumor role in the tumor microenvironment (TME), and more M1 infiltration means better prognosis. Previous studies have developed algorithms to predict the fraction of M1 based on transcriptomic data, whereas few study focus on DNA methylation data.
Methods
A macrophage multiplex immunofluorescence (mIF) panel (including DAPI, panCK, CD68, CD86, IRF5, CD163 and CD206) and DNA methylation sequencing were used in lung adenocarcinoma (LUAD) patients’ formalin-fixed paraffin-embedded samples. The fraction of M1 (with more positive M1 markers [CD86 and IRF5] than M2 markers [CD163 and CD206]) was calculated based on all macrophages (DAPI+panCK-CD68+). Patients were randomly divided into training cohort (70%) and test cohort (30%). The Pearson correlation and random forest algorithm were used to screened genes to build artificial neural network (ANN) models in the training cohort. Three hundred times of three-fold cross validation were performed to obtain 900 ANN models and test the accuracy of them. The final predicted value of the ANN system were equal to the weighted average of output values of all 900 ANN models. Finally, the accuracy of the ANN system was tested validated in the test cohort.
Results
Forty patients with LUAD were enrolled, and the median fraction of M1 was 3.27% (range: 0% to 30.91%). A total of 43 genes were with p-value < 0.001 were selected by Pearson correlation, and the top eight genes (C10orf90, ITGAX, TMED9, RGN, CENPF, LGI4, PPCS and KIAA1211) from random forest algorithm were used to build 900 three-layer ANN models. Each ANN model had eight input nodes, five hidden nodes and one output node. The frequency of ANN model whose weight > 0.70 (the accuracy > 0.70) was 74.78% (673/900). The Pearson correlation coefficient between the predicted value and the true M1 fraction was 0.89 (R2 = 0.79, p < 0.01) in the training cohort and 0.80 (R2 = 0.65, p < 0.01) in the test cohort.
Conclusions
DNA methylation data is more suitable to establish models than RNA data. In this study, an ANN system based on DNA methylation data was constructed and showed a potential value in predicting the fraction of M1 in LUAD, which could help to further understand the TME and identify patients that would benefit from immunotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2295P - Pan-cancer prevalence of MET fusions and clinical response to MET- targeted therapy
Presenter: Morana Vojnic
Session: Poster session 08
2296P - SGLT2 i dapagliflozin reduces NF-kB expression in heart and kidneys of preclinical models exposed to doxorubicin through MYd-88 and NLRP3 pathways
Presenter: Nicola Maurea
Session: Poster session 08
2297P - Gene co-expression networks capture the potential pathogenesis and progression of upper tract urothelial cancer
Presenter: Tingting Fu
Session: Poster session 08
2298P - Feasibility of ex vivo drug sensitivity testing in urothelial cancer: EVITA trial
Presenter: Mathijs Scholtes
Session: Poster session 08
2299P - Mebendazole enhances the anticancer effect of irinotecan and check-point inhibitor in vitro and in vivo
Presenter: Sharmineh Mansoori
Session: Poster session 08
2300P - Clonal hematopoiesis of indeterminate potential (CHIP) in patients with advanced NSCLC treated with immune checkpoint blockers (ICB) as monotherapy: Analysis of the PREMIS study
Presenter: Julieta Rodriguez
Session: Poster session 08
2301P - Combining cancer patient spatial transcriptomics and bulk RNA-Seq data to drive insights into NSCLC
Presenter: Julia Bischof
Session: Poster session 08
2302P - Efficacy assessment of targeted and immunotherapies for personalised treatment of melanoma using 2D and 3D ex-vivo assays
Presenter: Md Marufur Rahman
Session: Poster session 08
2303P - Protein functional interpretation of gene variants observed in clinical next-generation sequencing (NGS) for pleural mesothelioma
Presenter: Ferdinando Cerciello
Session: Poster session 08
2304P - A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19 -17)
Presenter: Eun Joo Kang
Session: Poster session 08